Effect of Galcanezumab on Total Pain Burden in Patients Who Had Previously Not Benefited from Migraine Preventive Medication (CONQUER Trial): A Post Hoc Analysis

被引：0
|
作者：
Jessica Ailani
Jeffrey Scott Andrews
Antje Tockhorn-Heidenreich
Richard Wenzel
Mallikarjuna Rettiganti
机构：
[1] Medstar Georgetown University,
[2] Eli Lilly and Company,undefined
来源：
Advances in Therapy | 2022年 / 39卷
关键词：
CONQUER trial; Galcanezumab; Migraine; Prior preventive failures; Total pain burden;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4544 / 4555
页数：11
相关论文
共 50 条
  • [31] Effects of Galcanezumab on Health-Related Quality of Life and Disability in Patients with Previous Failure of 2-4 Migraine Preventive Medication Categories: Results from a Phase IIIb Randomized, Placebo-Controlled, Multicenter Clinical Trial (CONQUER)
    Tepper, Stewart J.
    Ailani, Jessica
    Ford, Janet H.
    Nichols, Russell M.
    Li, Lily Q.
    Kemmer, Phebe
    Hand, Austin L.
    Tockhorn-Heidenreich, Antje
    CLINICAL DRUG INVESTIGATION, 2022, 42 (03) : 263 - 275
  • [32] Impact of Galcanezumab on Total Pain Burden: Findings from Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies in Patients with Episodic or Chronic Migraine
    Ailani, Jessica
    Andrews, J. Scott
    Rettiganti, Mallikarjuna
    Nicholson, Robert
    NEUROLOGY, 2020, 94 (15)
  • [33] EFFECTS OF GALCANEZUMAB ON ACUTE MEDICATION USE AND HEALTH CARE RESOURCE UTILIZATION IN PATIENTS WITH TREATMENT-RESISTANT MIGRAINE: RESULTS FROM A RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL (CONQUER)
    Ford, Janet
    Gomez, Julio Pascual
    Stroud, Chad
    Rettiganti, Mallikarjuna
    Estemalik, Emad
    Day, Kathleen
    Ambrosini, Anna
    CEPHALALGIA, 2020, 40 : 45 - 46
  • [34] A POST HOC ANALYSIS OF FACTORS ASSOCIATED WITH SIGNIFICANT REDUCTION IN MIGRAINE HEADACHE DAYS FROM THREE PHASE 3 PLACEBO-CONTROLLED TRIALS OF PATIENTS WITH EPISODIC AND CHRONIC MIGRAINE TREATED WITH GALCANEZUMAB
    Aurora, S. K.
    Ruff, D. D.
    Zhang, Q.
    Pearlman, E. M.
    CEPHALALGIA, 2018, 38 : 81 - 82
  • [35] Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial
    Ashina, Messoud
    Lipton, Richard B.
    Ailani, Jessica
    Versijpt, Jan
    Sacco, Simona
    Mitsikostas, Dimos D.
    Christoffersen, Cecilie Laurberg
    Sperling, Bjorn
    Ettrup, Anders
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (02)
  • [36] Benefit-Risk assessment of atogepant vs. placebo in participants with episodic migraine who had prior inadequate response to 2-4 classes of oral preventive treatment: a post-hoc analysis of the ELEVATE trial
    Reuter, U.
    Lalla, A.
    Sacco, S.
    Holle-Lee, D.
    Pozo-Rosich, P.
    Nagy, K.
    Luo, L.
    Carr, K.
    Gandhi, P.
    Tassorelli, C.
    JOURNAL OF HEADACHE AND PAIN, 2024, 25
  • [37] CHARACTERIZATION OF PATIENTS WHO HAD ≥5% WEIGHT LOSS WITH ONCE-NIGHTLY SODIUM OXYBATE: POST HOC ANALYSIS FROM REST-ON
    Roth, T.
    Morse, A. M.
    Bogan, R.
    Roy, A.
    Dubow, J.
    Gudeman, J.
    Dauvilliers, Y.
    SLEEP MEDICINE, 2024, 115 : 209 - 209
  • [38] Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    Imai, Noboru
    Isogai, Yuki
    Shibasaki, Yoshiyuki
    Nakai, Masami
    Ishida, Miki
    Ning, Xiaoping
    Koga, Nobuyuki
    NEUROLOGY AND THERAPY, 2023, 12 (06) : 1981 - 1991
  • [39] Effects of Fremanezumab on Medication Overuse in Japanese Chronic Migraine Patients: Post Hoc Analysis of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
    Noboru Imai
    Yuki Isogai
    Yoshiyuki Shibasaki
    Masami Nakai
    Miki Ishida
    Xiaoping Ning
    Nobuyuki Koga
    Neurology and Therapy, 2023, 12 : 1981 - 1991
  • [40] Baseline characteristics of patients with and without hypercoaguable sepsis and the effect of afelimomab on mortality: a post hoc analysis from the MONARCS trial
    E Panacek
    S Johnson
    D Johnson
    T Albertson
    J Marshall
    B Barchuk
    L Teoh
    Critical Care, 5 (Suppl 1):
12345